I n 1941, Huggins and Hodges first demonstrated that prostate cancers are driven by androgens, and that androgen deprivation therapy (ADT) is highly active against prostate cancer. 7 ADT, which lowers testosterone to castration levels, remains the mainstay of systemic treatment. It is still used as an initial treatment for metastatic prostate cancer and will usually continue throughout the duration of all other anti-cancer treatments. ADT is typically a luteinising hormone-releasing hormone (LHRH) agonist that blocks the hypothalamic-pituitary-testicular axis.
90% of patients respond to ADT, with a failure-free survival of approximately 45 months. 2 ADT is usually given as an injection every three months by the patient's general practice, although six-monthly preparations are also available. The occurrence of the 'flare' phenomenon, whereby LHRH agonists can cause a transient increase in testosterone levels resulting in an initial worsening of symptoms, remains controversial. 8 To prevent a potential 'flare', an antiandrogen should be started two weeks prior to initiation of LHRH agonists.
If men present with metastatic disease they are referred to as having metastatic hormone-sensitive prostate cancer (mHSPC) (Figure 1 ). Once the testosterone level is <50ng/dL on ADT, the patient is referred to as having metastatic castrationresistant prostate cancer (mCRPC). 
CHEMOTHERAPY

Docetaxel
Chemotherapy was first shown to demonstrate a survival benefit in prostate cancer in 2004 in mCRPC, leading to the licensing of docetaxel, a taxane mitotic inhibitor, as a treatment for mCRPC. 9, 10 Docetaxel is given intravenously every 21 days for up to 10 doses.
In 2014, the CHAARTED study showed the addition of docetaxel to ADT significantly improved overall survival in mHSPC by around 14 months (58 versus 44 months). 1 The absolute benefit in survival was greater in the subgroup with high-volume disease, as described in Table 1 .
In 2015 the results of the STAMPEDE trial were published. This large phase 3, randomised controlled trial compared men with both high-risk locally advanced prostate cancer and metastatic prostate cancer, receiving six doses of docetaxel with ADT, compared to ADT alone. 2 It demonstrated an overall survival benefit of 10 months (from 71 to 81 months) in those receiving docetaxel in addition to ADT. The difference was even greater in the subgroup of patients with metastatic disease, with an overall survival benefit of 15 months (45 versus 60 months). The toxicity profiles in both trials were acceptable. 1, 2 In fact, men may tolerate chemotherapy better earlier in their disease course when they are fitter.
In contrast, the results of the GETUG-AFU trial showed that there was no statistically significant survival benefit when giving docetaxel in the hormone-sensitive setting. 11 However, a meta-analysis of 2992 patients from five randomised controlled trials, including CHAARTED, STAMPEDE and GETUG-AFU, showed an absolute improvement in four-year survival of 9% when giving docetaxel in the hormone sensitive setting. 3 We believe the evidence is compelling and that clinicians should now discuss six cycles of 'upfront' docetaxel with all patients with mHSPC who are fit enough to receive chemotherapy. This means that
Treatment
Trial, year of publication patients with metastatic disease should be referred to an oncologist at diagnosis, and be managed within the multidisciplinary prostate cancer team.
Cabazitaxel (Jevtana)
Cabazitaxel is a second-generation microtubule inhibitor, licensed in mCRPC post-docetaxel chemotherapy where relapse has occurred. In comparison to mitoxantrone it has been shown to improve overall survival by 3.4 months (15.1 versus 12.7 months) after prior treatment with docetaxel. 12 Cabazitaxel is generally not as well tolerated as docetaxel and has significant toxicities associated with it, most notably haematological side-effects such as neutropenia and anaemia. 12
SECOND-GENERATION ANDROGEN RECEPTOR TARGETED THERAPIES Enzalutamide (Xtandi)
Enzalutamide is an oral second-generation anti-androgen that blocks androgen binding to the androgen receptor, inhibits androgen receptor nuclear translocation, and impairs the androgen receptor binding to DNA, thus preventing gene expression and the growth, survival and proliferation of prostate cancer cells.
The PREVAIL trial, a randomised, doubleblind phase 3 trial of enzalutamide versus placebo in the pre-docetaxel setting, showed an overall survival benefit of 2.2 months with enzalutamide versus placebo (32.4 versus 30.2 months respectively, p<0.001). 6 In addition, enzalutamide delayed the time to the first skeletalrelated event, including fracture and the need for palliative radiotherapy.
Enzalutamide is licensed and NICEapproved in the pre-and post-docetaxel setting. It is generally well tolerated, but the main side-effects patients experience are fatigue, diarrhoea, hot flushes, musculoskeletal pains and headache. In the AFFIRM trial, 5 out of 800 patients in the enzalutamide arm had seizures, and enzalutamide is therefore contraindicated in any patient with a history of seizures. 4
Abiraterone (Zytiga)
Abiraterone is an androgen biosynthesis inhibitor that inhibits CYP17 (which is expressed in prostatic tumour tissues) and is required for androgen biosynthesis. Abiraterone, like enzalutamide, is a once-daily oral medication, but unlike enzalutamide is given with 5mg prednisolone twice daily.
Abiraterone with prednisolone has demonstrated an overall survival benefit of 4.6 months (15.8 versus 11.2 months) when compared to prednisolone alone in the post-docetaxel setting in metastatic prostate cancer. 5 It has shown a similar survival benefit of 4.4 months when given prior to docetaxel. 8 Side-effects are rare, but include fatigue, fluid retention, hypertension, cardiac disorders, hypokalaemia and liver dysfunction. 5, 13 As patients may be on abiraterone with prednisolone for a significant amount of time, clinicians must address potential long-term complications of steroid use, most notably hypertension, diabetes, weight gain and cardiovascular risk factors.
Abiraterone, like enzalutamide, is licensed and NICE-approved in the pre-and postdocetaxel setting. In 2017, two phase 3 trials demonstrated a survival benefit when combining abiraterone (and prednisolone) with ADT in the hormone-sensitive setting (prior to docetaxel). STAMPEDE, which included men with locally advanced and metastatic disease, demonstrated a threeyear survival rate of 83% in the abiraterone/ ADT group versus 76% in the ADT alone group. 14 LATITUDE only included patients with metastatic disease, and demonstrated a significantly longer median overall survival in the abiraterone group (not reached versus 34.7 months). 15 As a result, abiraterone has recently been licensed for the treatment of newly diagnosed high-risk mHSPC in combination with ADT.
Abiraterone or enzalutamide?
Although there have been no headto-head trials of abiraterone and enzalutamide, the efficacy of the drugs appears to be similar. 4, 6, 13 A decision regarding which drug to choose should be made depending on the patient's comorbidities and the side-effect profile of the drugs. There are insufficient data to support the sequential use of abiraterone and enzalutamide and vice versa. [16] [17] [18] Many studies aiming to evaluate the efficacy of this approach have small numbers of patients and are retrospective. Therefore, when treating patients within the NHS, the clinician must choose between one drug and the other. The only indication to switch drug is due to side-effects, and this must be within the first three months of starting treatment.
Radium-223 (Xofigo)
Radium-223 is an alpha-emitting calcium mimetic that selectively binds to areas of increased bone turnover and has a highly localised cytotoxic effect. This minimises the effect on the bone marrow while effectively treating bony metastatic disease. In 2013 the ALSYMPCA trial showed that radium-223 was the first bone-targeted intervention to show an improvement in survival for patients with metastatic prostate cancer. 19 As well as demonstrating an overall survival benefit of 3.6 months (14.9 versus 11.3 months) in comparison to placebo, radium-223 also increased the time to the first skeletal-related event (eg fracture, malignant spinal cord compression) or the need for palliative radiotherapy by 5.8 months. This is likely to have a significant impact on the quality of life for patients affected by metastatic bone disease. The side-effects of radium-223 are rare, but include nausea, anaemia, fatigue, diarrhoea and constipation. Radium-223 is given as an intravenous infusion every four weeks for six months in commissioned centres in collaboration with the treating oncologist and nuclear medicine specialists. Figure 2 represents the typical current sequencing of treatments in a newly diagnosed patient with metastatic prostate cancer. Patients should continue ADT throughout all of their treatments and should be considered for clinical trials at all times.
SEQUENCING
THE FUTURE
Despite significant advances being made in the treatment of metastatic prostate cancer, there are still several unanswered questions. These include drug sequencing, the role of combinations, mechanisms of resistance, and the use of biomarkers to select the best treatment with the lowest toxicity.
Furthermore, trials looking at the combination of different treatments, such as dual androgen-receptor blockade with enzalutamide with abiraterone, are ongoing. 20 Trials are also looking at earlier sequencing of drugs, such as combining enzalutamide with 'upfront' docetaxel. 21 Combinations of drugs may have the potential to overcome mechanisms of resistance and maximise benefit from available drugs.
In future, novel treatments are likely to move beyond those targeting the androgen receptor. For example, it is now recognised that DNA repair abnormalities such as BRCA2 mutations are frequently found in men with metastatic prostate cancer. The use of poly adenosine diphosphate-ribose polymerase (PARP) inhibitors (such as those used in breast cancer) is likely in men harbouring these mutations in the future.
CONCLUSION
As the number of treatments available for metastatic prostate cancer has increased, treatment has become much more complex. Therefore, patients should be managed in specialist multidisciplinary teams and offered entry into clinical trials that help answer the questions around drug sequencing. General practitioners remain an integral part of this team, from diagnosis to palliation. 
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